Top

European Journal of Medical Research

Published in:

Open Access 01-12-2017 | Research

The effects of body weight loss and gain on arterial hypertension control: an observational prospective study

Authors: Peter Sabaka, Andrej Dukat, Jan Gajdosik, Matej Bendzala, Martin Caprnda, Fedor Simko

Published in: European Journal of Medical Research | Issue 1/2017

Abstract

Background

Body weight changes are associated with significant variations in blood pressure (BP). Body mass modifications may, therefore, influence hypertension control in primary care.

Methods

Patients with a history of essential arterial hypertension were observed for 12 months. Anthropometric data and clinical BP were evaluated at the time of the recruitment and after 12 months of follow-up. The association between (body mass index) BMI change and BP control was analyzed by logistic regression.

Results

Sixteen thousand five hundred and sixty-four patients were recruited, while 13,631 patients (6336 men; 7295 women) finished the 1-year follow-up. In obese patients, a BMI decrease by at least 1 kg/m² was negatively associated with uncontrolled hypertension at the end of the follow-up (men p < 0.0001, OR = 0.586, 0.481–0.713, women p < 0.001, OR = 0.732, 0.611–0.876). A similar association was observed in overweight patients (men p < 0.05, OR = 0. 804, 95% CI: 0.636–0.997, women p < 0.05, OR = 0.730, 95% CI: 0.568–0.937). A BMI increase of at least 1 kg/m² was associated with a significantly higher odd of uncontrolled hypertension in obese (men p < 0.001, OR = 1.471, 1.087–1.991, women p < 0.001, OR = 1.422, 1.104–1.833) and overweight patients (men p < 0.0001, OR = 1.901, 95% CI: 1.463–2.470, women p < 0.0001, OR = 1.647, 95% CI: 1.304–2.080).

Conclusions

Weight loss is inversely associated and weight increase is positively associated with the probability of uncontrolled hypertension in obese and overweight hypertensives.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–52.CrossRefPubMed

Chiang HH, Tseng FY, Wang CY, Chen CL, Chen YC, See TT, et al. All-cause mortality in patients with type 2 diabetes in association with achieved hemoglobin A_1c, Systolic blood pressure, and low-density lipoprotein cholesterol levels. PLoS ONE. 2014;9:e109501. doi:10.1371/journal.pone.0109501.CrossRefPubMedPubMedCentral

Simko F, Pechanova O. Remodelling of the heart and vessels in experimental hypertension: advances in protection. J Hypertens. 2010;28(Suppl 1):S1–6. doi:10.1097/01.hjh.0000388487.43460.db.CrossRefPubMed

Paulis L, Matuskova J, Adamcova M, Pelouch V, Simko J, Krajcirovicova K, et al. Regression of left ventricular hypertrophy and aortic remodelling in NO-deficient hypertensive rats: effect of l-arginine and spironolactone. Acta Physiol. 2008;194:45–55. doi:10.1111/j.1748-1716.2008.01862.x (Epub 2008 Apr 16).CrossRef

Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255–66. doi:10.1016/S0140-6736(09)61966-8 (Epub 2010 Mar 16).CrossRefPubMed

Ikeda N, Sapienza D, Guerrero R, Aekplakorn W, Naghavi M, Mokdad AH, Lozano R, Murray CJ, et al. Control of hypertension with medication: a comparative analysis of national surveys in 20 countries. Bull World Health Organ. 2014;92:10–9. doi:10.2471/BLT.13.121954.CrossRefPubMed

Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:766–81. doi:10.1016/S0140-6736(14)60460-8 (Epub 2014 May 29).CrossRefPubMedPubMedCentral

Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311:806–14. doi:10.1001/jama.2014.732.CrossRefPubMedPubMedCentral

Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci. 2002;324:127–37.CrossRefPubMed

10.

Re RN. Obesity-related hypertension. Ochsner J. 2009;9:133–6.PubMedPubMedCentral

11.

Andrade FCD, Vazquez-Vidal I, Flood T, et al. One-year follow-up changes in weight are associated with changes in blood pressure in young Mexican adults. Public Health. 2012;126:535. doi:10.1016/j.puhe.2012.02.005.CrossRefPubMed

12.

Neter JE, Stam BE, Kok FJ, Grobbee DE, Gelseijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42:878–84.CrossRefPubMed

13.

Whelton PK, Appel L, Charleston J, Dalcin AT, Ewart C, Fried L, Kaidy D, Klag MJ, Kumanyika S, Steffen L, Walker WG. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention phase 1. JAMA. 1992;267:1213–20.CrossRef

14.

Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: Trials of Hypertension Prevention, phase II. Ann Intern Med. 2001;134:1–11.CrossRefPubMed

15.

Siebenhofer A, Jeitler K, Horvath K, Berghold A, Siering U, Semlitsch T. Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database Syst Rev. 2013;3:CD007654.

16.

Symonds B. Blood pressure of healthy men and women. JAMA. 1923;8:232–6.CrossRef

17.

Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968–77.CrossRefPubMed

18.

Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357. doi:10.1097/01.hjh.0000431740.32696.cc.CrossRefPubMed

19.

State Institute for Drug Control: The SIDG register. http://www.sukl.eu/. Accesed 28 Aug 2015.

20.

Sabaka P, Kruzliak P, Gaspar L, Caprnda M, Bendzala M, Balaz D, et al. Postprandial changes of lipoprotein profile: effect of abdominal obesity. Lipids Health Dis. 2013;12:179. doi:10.1186/1476-511X-12-179.CrossRefPubMedPubMedCentral

21.

Kalupahana NS, Moustaid-Moussa N. The renin-angiotensin system: a link between obesity, inflammation and insulin resistance. Obes Rev. 2012;13:136–49. doi:10.1111/j.1467-789X.2011.00942.x (Epub 2011 Oct 31).CrossRefPubMed

22.

Thethi T, Kamiyama M, Kobori H. The Link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep. 2012;14:160–9. doi:10.1007/s11906-012-0245-z.CrossRefPubMedPubMedCentral

23.

Mark AL, Shaffer RA, Correia ML, Morgan DA, Sigmund CD, Haynes WG. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J Hypertens. 1999;17:1949–53.CrossRefPubMed

24.

Huby AC, Otvos L Jr, Belin de Chantemèle EJ. Leptin induces hypertension and endothelial dysfunction via aldosterone-dependent mechanisms in obese female mice. Hypertension. 2016;67:1020–8. doi:10.1161/HYPERTENSIONAHA.115.06642 (Epub 2016 Mar 7).CrossRefPubMedPubMedCentral

25.

Sechi M, Leonardo A. Mechanisms of insulin resistance in rat models of hypertension and their relationships with salt sensitivity. J Hypertens. 1999;17:1229–37.CrossRefPubMed

26.

Zhou M-S, Wang A, Yu H. Link between insulin resistance and hypertension: what is the evidence from evolutionary biology? Diabetol Metab Synd. 2014;6:12. doi:10.1186/1758-5996-6-12.CrossRef

27.

Mao Y, Tokudome T, Kishimoto I. Ghrelin and blood pressure regulation. Curr Hypertens Rep. 2016;18:15. doi:10.1007/s11906-015-0622-5.CrossRefPubMed

28.

D’Agati VD, Chagnac A, de Vries AP, Levi M, Porrini E, Herman-Edelstein M, et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol. 2016;12:453–71. doi:10.1038/nrneph.2016.75.CrossRefPubMed

29.

Sjostrom CD, Peltonen M, Wedel H, Sjostrom L. Differential long-term effects of intentional weight loss on diabetes and hypertension. Hypertension. 2000;36:20–5.CrossRefPubMed

30.

Shah NR, Braverman ER. Measuring adiposity in patients: the utility of body mass Index (BMI), percent body fat, and leptin. PLoS ONE. 2012;7(4):e33308. doi:10.1371/journal.pone.0033308.CrossRefPubMedPubMedCentral

Title: The effects of body weight loss and gain on arterial hypertension control: an observational prospective study
Authors: Peter Sabaka
Andrej Dukat
Jan Gajdosik
Matej Bendzala
Martin Caprnda
Fedor Simko
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: European Journal of Medical Research / Issue 1/2017
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-017-0286-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The effects of body weight loss and gain on arterial hypertension control: an observational prospective study

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Platelet-rich plasma stimulates angiogenesis in mice which may promote hair growth

Fully digital data processing during cardiovascular implantable electronic device follow-up in a high-volume tertiary center

The effect of lipoaspirates vs. dissected abdominal fat on breast cancer cells in vitro

High sensitivity troponin T and I reflect mitral annular plane systolic excursion being assessed by cardiac magnetic resonance imaging

A study on relationship between elderly sarcopenia and inflammatory factors IL-6 and TNF-α

Left innominate vein stenosis in an asymptomatic population: a retrospective analysis of 212 cases